Advertisement

Topics

Neurotech launches phase II NT-501 results for Macular Telangiectasia

09:38 EDT 21 Jun 2017 | CentreWatch

Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), has announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macular Telangiectasia type 2 (MacTel). The multicenter, randomized clinical trial demonstrated a statistically significant reduction in the progressive loss of photoreceptors in treated versus untreated […]

The post Neurotech launches phase II NT-501 results for Macular Telangiectasia appeared first on CenterWatch News Online.

Original Article: Neurotech launches phase II NT-501 results for Macular Telangiectasia

NEXT ARTICLE

More From BioPortfolio on "Neurotech launches phase II NT-501 results for Macular Telangiectasia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...